Abstract: The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).

Abstract: The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).

Abstract: The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).

Abstract: The invention relates to the combined use of at least one monoterpene which can be applied systemically, in particular perorally, and at least one respiratory tract therapeutic agent which can be applied topically, in particular through inhalation, for the prophylactic and/or therapeutic treatment, in particular combination therapy and/or co-medication, of respiratory tract diseases, in particular bronchopulmonary diseases. Through the combined use of the systemic monoterpene with the topical, in particular inhaled respiratory tract therapeutic agent, the effect or efficiency of the topical or inhaled respiratory disease therapeutic agent can be increased significantly, in particular in a synergistic manner, on the one hand, and the required dosage thereof can be reduced significantly on the other hand, combined with the resulting advantages (e.g., avoidance or reduction of side effects).

Abstract: The invention relates to a dosage form containing cineole for peroral application in capsule form, wherein the dosage form containing cineole is designed as a capsule-in-capsule system, wherein the capsule-in-capsule system has an outer capsule (outside capsule) having an outer capsule shell and a plurality of inner capsules (inside capsules) located in the outer capsule, wherein the inner capsules are completely enclosed by the capsule shell of the outer capsule and the inner capsules are designed as microcapsules, which each contain the active ingredient 1,8-cineole. The invention further relates to the production and use of said dosage form containing cineole.

Abstract: The present invention relates to a pharmaceutical composition suitable for the prophylactic and/or curative topical treatment of rhinitis, said composition containing in combination and in each case in pharmaceutically efficacious amounts: (a) at least one sympathomimetic suitable for topical application and having vasoconstrictor action and/or detumescent action on the mucous membrane or its physiologically acceptable salts or derivatives; and (b) at least one preferably acidic glycosaminoglycan or its physiologically acceptable salts or derivatives, in particular hyaluronic acid or its salts.

Abstract: The invention relates to the use of vervain and/or ribwort, either alone or else as a mixture of the two herbs or of their respective constituents or extracts, for the prophylactic or curative topical treatment of dental and periodontal diseases, such as, for example, dental decay, gingivitis, periodontosis and plaque, and also to a corresponding pharmaceutical composition which contains vervain and/or ribwort or their respective constituents or extracts.

Abstract: The present invention relates to a pharmaceutical composition suitable for the prophylactic and/or curative topical treatment of rhinitis, said composition containing in combination and in each case in pharmaceutically efficacious amounts: (a) at least one sympathomimetic suitable for topical application and having vasoconstrictor action and/or detumescent action on the mucous membrane or its physiologically acceptable salts or derivatives; and (b) at least one preferably acidic glycosaminoglycan or its physiologically acceptable salts or derivatives, in particular hyaluronic acid or its salts.

Abstract: A pharmaceutical preparation for the treatment of acute rhinitis contains, in combination and in physiological concentration, a) a sympathomimetic having a 2-imidazoline structure which is suitable for topical use or its physiologically acceptable salts; and b) a pantothenic functional compounds which is b1) pantothenol or its derivatives, in particular esters; and/or b2) pantothenic acid or its physiologically acceptable salts.